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Abstract
Background Pearson marrow-pancreas syndrome (PS) is
usually a fatal mitochondrial disease, mostly diagnosed
during infancy or postmortem. PS is caused by the deletions
or duplications of mitochondrial DNA (mtDNA). The tissue
distribution and relative proportions of expressed abnormal
mtDNA determine the phenotype and the clinical course.
Materials and methods We describe the case of a term baby
boy who was diagnosed with PS early in the neonatal
period due to severe aregenerative anemia and persistent
lactic acidosis.
Results His neurological examination was abnormal since
birth. Brain magnetic resonance imaging (MRI) at term was
abnormal, indicating that mitochondrial encephalopathy in
PS can be already manifested in the neonatal period. To our
knowledge, neonatal encephalopathy in PS has not been
previously described.
Conclusion PS is a rare condition diagnosed in the
newborn. It should be suspected in the presence of severe
anemia and persistent lactic acidosis, and may manifest
with early encephalopathy.
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Abbreviations
ADC Apparent diffusion coefficient
KSS Kearns-Sayre syndrome
MRI Magnetic resonance imaging
MRS Magnetic resonance spectroscopy
mtDNA Mitochondrial DNA
PLIC Posterior limb of the internal capsule
PS Pearson syndrome
Introduction
Pearson marrow-pancreas syndrome (PS) is a rare multi-
systemic mitochondriopathy with lactic acidosis and non-
neuromuscular initial expression involving the hematopoietic
tissue, the exocrine pancreas, the liver, and the kidneys [7].
The typical clinical course is characterized by progressive
liver failure and intractable metabolic acidosis, with death in
infancy. Survivors later develop neurological symptoms,
such as in Kearns-Sayre syndrome (KSS) [6].
PS is frequently diagnosed in early infancy, but rarely
during the neonatal period. Prenatal hematological mani-
festations of PS have also been described [3]. The cause of
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the disease is most often de novo deletions or, more rarely,
duplications in the mitochondrial DNA (mtDNA). Large-
scale duplications coexist, with deletions in some cases.
The diagnosis is confirmed by the Southern blot analysis of
white blood cells, which identifies mtDNA rearrangements.
The severity of the clinical manifestations and the rate of
disease progression are variable and correlate with the
mtDNA gene mutation load [9] and the distribution of
mutation expression [4]. Currently, only supportive treat-
ment is available.
We present the case of a child with PS diagnosed early in
the neonatal period, including a detailed description of the
neurological picture, brain magnetic resonance imaging
(MRI) scans and clinical follow-up until death at 18 months
of life.
Methods and results
Case report
A full-term boy was born after an uneventful pregnancy to
healthy unrelated parents of Swiss and North African origin.
His mother had chronic hepatitis C with no detectable viremia
and received adequate prenatal care. The baby presented intra-
uterine growth restriction, with birth weight 2,360 g (<per-
centile 10), length 47 cm (<percentile 10), and head
circumference 35.5 cm (percentile 10–50). The family history
was unremarkable; a 4-year-old sibling is healthy. Emergency
cesarean section was required for pre-eclampsia and altered
cardiotocogram. The Apgar score was 6/7/8 and cord blood
pH 7.17 and 7.27 (arterial and venous, respectively).
Following birth, the baby presented with extreme pallor, a
loud cardiac murmur, hepatomegaly, hyporeactivity, and
hypotonia. Within one hour after birth, in the setting of severe
anemia, he developed tachypnea and lactic acidosis, without
hypoglycemia or ketosis, consistent with a diagnosis of
cardiogenic shock. He required blood transfusions, pressure
support, and bicarbonate infusion, followed by endotracheal
intubation at 12 hours of life.
The first laboratory results at 1 hour of life showed
aregenerative microcytic anemia (hemoglobin 29 g/l,
normal range 135–215) and severe lactic acidosis (blood
lactate 14 mmol/l, normal range 0.63–2.44) in the absence
of hypoxia. An early echocardiography on day 1 of life
showed signs of chronic antenatal hypoxia with dilatation
of the coronary arteries and right cardiac hypertrophy. After
stabilization, the patient was extubated on day 3 of life.
Asymptomatic thrombocytopenia (thrombocytes 48 G/l,
normal range 150–350) associated with persistent aregener-
ative anemia were noted on day 5. We also observed a
persistent lactic acidosis (venous lactate 3–5 mmol/l,
normal range 0.63–2.44). Neurological examination
revealed an irritable baby unable to suck or swallow, with
a marked axial hypotonia and severe head lag. Peripheral
tone was normal, archaic reflexes were present, but no deep
tendon reflexes could be elicited. No tremor was noted. At
2 weeks of life, the patient presented with post-prandial
vomiting without signs of malabsorption (fecal elastase
within the normal limits for age). Liver and pancreatic tests
were normal. Gastroesophageal reflux was suspected and
the symptoms spontaneously improved with antireflux
positioning and nasogastric feeding.
At birth, a cerebral ultrasound showed periventricular
echogenicities and a right choroid cyst. Brain MRI, performed
at 10 days of age (corrected age,40 weeks), demonstrated no
cerebral congenital malformations and no hemorrhage.
Spectroscopy was abnormal, with increased peak of lactate
in the posterior white matter, but no other abnormal
metabolites (Fig. 1). Moreover, diffusely excessive high
signal intensity on T2-weighted images were noted in the
white matter (Fig. 2), with increased values (19×10−5 mm2/s,
normal range 15–16×10−5 mm2/s) on apparent diffusion
coefficient (ADC) maps. In addition, the posterior limb of
the internal capsule (PLIC) showed an abnormally low level
of myelination on inversion recovery T1 images (Fig. 3).
Extensive investigations were performed for the severe
anemia. The placental examination showed no sign of
abruptio or torn vasa praevia. Trans-placental hemorrhage
was excluded by a negative Kleihauer-Betke test. Acute
internal hemorrhage was ruled out with normal cerebral and
abdominal ultrasounds. There was no hemoglobinopathy, no
hemolysis, nor jaundice. Coombs’ test was negative and
glucose-6-phosphate dehydrogenase activity was normal.
Infectious screening was negative for parvovirus B19,
cytomegalovirus, Epstein-Barr virus, malaria, and syphilis.
Hepatitis C screening was positive for IgG (60 times the
norm) but negative for hepatitis C antigen, consistent with
maternal infection. On day 4 of life, metabolic investigations
showed elevated Krebs cycle metabolites in the urine:
fumarate 174 mmol/mol creatinine (normal range 4.2–21.9),
malate 252 mmol/mol creatinine (normal range 10.8–47.8), 2-
oxoglutarate 423 mmol/mol creatinine (normal range 58.7–
338.6), and lactate 1,327 mmol/mol creatinine (normal range
25.9–91.9). Lactate was also elevated in the cerebrospinal
fluid (5.53 mmol/l, normal range<1.8 mmol/l), raising the
suspicion of a mitochondrial disorder. Bone marrow aspira-
tion and genetic testing were performed on day 19 of life.
Bone marrow smear demonstrated a sideroblastic anemia with
vacuolated erythroblasts, the hallmark findings for PS [1].
This diagnosis was confirmed by the Southern blot study of
the mtDNA, which revealed a 4.7-Kb deletion, with 60%
heteroplasmy in blood and bone marrow leucocytes.
At 1 month of life, the patient developed pancytopenia
with anemia requiring several blood transfusions, leucopenia,
and transient agranulocytosis. By 2 months of life, the
312 Eur J Pediatr (2009) 168:311–315
difficulty in sucking and swallowing had resolved spontane-
ously. The neurological status remained pathological, with
axial hypotonia being the most prominent clinical feature.
The baby was discharged with the implementation of a
multidisciplinary network of care and family support.
Follow-up until 1 year of age was characterized by persistent
failure to thrive (weight <percentile 3; length at percentile 3;
head circumference at percentile 50–75) and by several
hospital admissions due to viral infections (gastroenteritis,
Varicella-Zoster infection), as well as bacterial pneumonia.
Anemia was corrected with erythrocyte transfusions every
three weeks. Moderate to severe neutropenia (absolute
neutrophile count 0.5–1.5 G/l, normal range 1.0–9.0) and
moderate thrombocytopenia (thrombocytes 45–100 G/l,
normal range 150–350) persisted. Urinary organic acids
showed persistent increased excretion of lactate and Krebs
cycle intermediates. Chronic lactic acidosis required oral
bicarbonate treatment. Orotic acid was measured at least
three times and was never elevated (maximum value
0.96 mmol/mol creatinine, normal value <3.3). No diabetes
Fig. 2 T2-weighted transverse image at the level of the upper part of
the lateral ventricules shows a diffusely excessive high signal intensity
in the white matter
Fig. 1 A magnetic resonance
imaging (MRI) spectroscopic
acquisition demonstrated a
normal level of choline,
creatine, and N-acetyl-aspartate.
A mild signal of lactate is
observed in the posterior white
matter (arrow)
Fig. 3 Inversion T1-weighted transverse image at the level of the
basal ganglia demonstrates an abnormally low level of myelinization
of the posterior limb of the internal capsule (PLIC) (arrows)
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developed. At 1 year of age, neurological examination
revealed intact cranial nerves, persistent axial and peripheral
hypotonia, and no tremor. Developmental milestones were
severely delayed for motor skills (no sitting nor standing),
without apparent cognitive impairment. Exocrine pancreatic
insufficiency manifested with chronic diarrhea and weight
loss; oral enzymatic replacement was initiated. By the age of
15 months, the general condition of the patient worsened,
with rapid neurological deterioration. After extensive dis-
cussion with the parents, supportive care was withdrawn and
blood transfusions were stopped. The patient died at
18 months of life during sleep in a comfort care setting.
Postmortem examination was declined.
Neuroradiological analyses
Magnetic resonance imaging and spectroscopy (MRI and
MRS) scans were acquired on a 1.5-Tesla MR scanner in a
multichannel head coil. Five-mm transverse slices were used
for T2-weighted, inversion recovery T1-weighted, T2*-
weighted, and diffusion-weighted (b values of 0, 500, and
1,000 were used to calculate the ADC maps). MRS data was
acquired in a multivoxel mode at an echo time of 135 ms.
Molecular genetic analyses
DNA was extracted from leucocytes from blood and bone
marrow with a commercial DNA extraction kit (Nucleon,
Amersham). The deletion was identified using the multiplex
ligation-dependent probe amplification (MLPA) P125 Mito
probemix (MRC Holland Amsterdam, the Netherlands). The
kit contains 31 different probes, which allows the estimation
of the deletion size with an accuracy of ±30 bp. Confirma-
tion of the deletion was performed by Southern blot analysis
using standard techniques (analysis performed in the
Laboratory of Molecular Genetics, Division of Medical
Genetics, Geneva University Hospital, Switzerland).
Discussion
Pearson marrow-pancreas syndrome (PS) is a fatal multi-
systemic mitochondrial disorder rarely diagnosed in the
neonatal period. Onset is usually in early infancy, with
sideroblastic anemia, neutropenia, thrombocytopenia, gastro-
intestinal symptoms, failure to thrive, metabolic acidosis
with hyperlactic acidemia, and progressive liver and pancre-
atic failure [1, 5, 8, 10]. The diagnosis of PS is strongly
suspected when bone marrow aspirate shows the classical
normal cellularity with vacuolization of marrow precursors.
This genetic disorder, caused by mitochondrial DNA
(mtDNA) rearrangements, was first described by Pearson et
al. in 1979 [7]. The tissue distribution and relative
proportions of abnormal mtDNA gene products appear to
determine the phenotype and clinical course [4, 9].
Although no “typical” presentation of PS exists, unex-
plained aregenerative anemia and failure to thrive with
malabsorption in infancy are the most frequently reported
symptoms. These non-specific symptoms may lead to
extended work-up and delayed diagnosis. The early
diagnosis of PS has been reported postnatally [3] and
mostly in postmortem examinations of newborn infants
whose death occurred after acute intractable metabolic
acidosis and liver failure [1, 8].
Our patient presented at birth with severe neonatal
anemia, major hypotonia, and lactic acidosis, suggesting
the diagnosis of PS. During his first year of life, he had a
poor clinical course with multiple hospital admissions, and
was treated conservatively. He developed failure to thrive
with developmental delay. Exocrine pancreatic insufficiency
occurred later, without diabetes. To our knowledge, this is
the first report of such an early diagnosis of PS in a living
child, and also the first description of encephalopathy and
neuroradiological anomalies in a neonatal presentation of PS.
PS with neurological manifestations is well described in
older children [6, 11]. Neurological findings are either non-
specific, including mainly hypotonia, developmental delay,
ataxia and tremor, or typical KSS. Our patient presented
with an abnormal neurological status from birth. His
symptoms were initially thought to reflect cerebral hypoxia
resulting from the profound anemia, but a typical pattern of
hypoxic-ischemic encephalopathy was not found on subse-
quent imaging (10 days of life). Therefore, a correlation
between the abnormal neurological examination, abnormal
MRI findings, and a mitochondrial disease was postulated.
Note that non-specific neurological symptoms and MRI
findings are described very often in PS [6, 11], but not at
such an early age.
Lee et al. [6] described two extreme groups of patients
with PS and neurological symptoms: one group with death
before 4 years, the other with survival to later ages and the
development of ataxia, tremor, KSS, or Leigh syndrome.
Valanne et al. [11] reported cognitive impairment being the
most common neurological symptom in PS survivors.
Brain MRI abnormalities have been described in a
variety of mitochondrial disorders [2]. In our patient, brain
MRI performed at term demonstrated early non-specific
cerebral anomalies. Although brain imaging at this age is
too early to represent the complete PS central nervous
system involvement, similar findings are well described in
previous reports. A broad range of images has been
reported from normal findings to non-specific lesions,
regardless of the clinical neurological course [6, 11].
Interestingly, the diffusely excessive high signal intensity
seen in the white matter on T2-weighted images, with
increased measurements of ADC values (Fig. 2), have also
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been described in children and adults with KSS/PS [11].
These MRI observations might be explained by a vacuoli-
zation involving the neuritic processes, which is thought to
be the pathological process in mitochondrial deletion
syndrome. Mitochondrial diseases are caused by defects in
intracellular energy production. Tissues with high-energy
requirements, like the brain, are extremely sensitive. PS
patients have a large-scale mtDNA mutation range. MRI
findings in PS with neurological involvement are well
described. Although no direct genotype–phenotype corre-
lation is known in PS, there is possibly a correlation
between the degree of intracellular energy production
impairment, the clinical neurological manifestations, and
the corresponding imaging findings. The posterior limb of
the internal capsule (PLIC) has also been described as
frequently abnormal in metabolic diseases (Fig. 3). This
may be the first objective manifestation of demyelinating
lesions in the white matter in mitochondrial diseases [2].
Moreover, the lactate detected by spectroscopy in the
posterior white matter (Fig. 1) is in favor of a pathogenetic
role of the respiratory chain disturbance on the white matter
changes. An elevation of brain lactate at MRS should raise
the suspicion of a respiratory chain deficiency in the
absence of hypoxia.
This case suggests that early neurological impairment,
associated with non-specific brain MRI and MRS anoma-
lies, could be the first neuropathologic expression of
neonatal PS. In our case, it would have been interesting to
perform follow-up brain MRI studies in order to analyze the
disease progression and to better understand the correlation
of imaging with the pathological neurological status.
Furthermore, a detailed study of the heteroplasmy of the
mtDNA deletion in different tissues would be relevant in
the future for the genetic characterization of PS in relation
to its clinical course and phenotypic expression. Unfortu-
nately, the patient’s poor general course lead to a
conservative therapeutic approach that did not warrant
unnecessary procedures. Moreover, the overwhelming
diagnosis of PS worsened a fragile psychosocial situation,
preventing the genetic screening of the mother to rule her
out as a carrier.
Most cases described with abnormal MRI are older than
our patient. This case is unique in terms of the precocity of the
diagnosis, the association of clinical neurological manifes-
tations, and the corresponding neuroimaging findings.
In conclusion, severe anemia with lactic acidosis and
neurological impairment at birth should raise the suspicion
of PS. The diagnosis may be confirmed quickly by bone
marrow aspiration at the bedside and the genetic testing of
peripheral blood to demonstrate the presence of mtDNA
mutations. Brain MRI anomalies might be visualized in the
neonatal period in PS. Follow-up brain MRI is mandatory
to assess disease progression and the development of
mitochondrial encephalopathy. A follow-up imaging at
6 months and 2 years of age would be recommended.
However, PS with neurological involvement remains a rare
entity with a variable spectrum of clinical and neuroradio-
logical patterns.
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